How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

345 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Raltegravir - HIV

in the incidence of serious adverse events, withdrawals due to adverse events or drug-related adverse events. Raltegravir costs $27 per day, which is similar or less than other antiretroviral agents approved for use in treatment-experienced patients who are not responding to initial therapy: $31 per day for darunavir boosted with ritonavir, $40 per day for tipranavir boosted with ritonavir, and $79 per day for enfuvirtide. Of Note: 1. Both published and unpublished data were reviewed and taken

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

162. Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1. (PubMed)

cross-resistance to the PIs most commonly used for salvage therapy: lopinavir (LPV), tipranavir (TPV), and darunavir (DRV). The panel of recombinant infectious molecular clones has been made available without restriction through the NIH AIDS Research and Reference Reagent Program. The public availability of the panel makes it possible to compare the inhibitory activities of different PIs with one another. The diversity of the panel and the high-level PI resistance of its clones suggest

Full Text available with Trip Pro

2013 Antimicrobial Agents and Chemotherapy

163. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. (PubMed)

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. Limited data are available on resistance to etravirine, rilpivirine, darunavir and tipranavir in patients infected with HIV-1 non-B subtypes, in which natural polymorphisms at certain positions could influence the barrier and/or pathways to drug resistance.FASTA format sequences from the reverse transcriptase and protease genes recorded within the Spanish Drug Resistance (...) frequent in B than non-B subtypes, whereas V90I was more prevalent in non-B subtypes. Despite these differences, the overall prevalence of resistance did not differ significantly when comparing etravirine or rilpivirine in B versus non-B subtypes (11.3% versus 7.4%, P = 0.13, and 10.5% versus 7.4%, P = 0.23, respectively). Despite more frequent natural polymorphisms in non-B than B subtypes at tipranavir resistance positions, the prevalence of tipranavir resistance was greater in B than non-B subtypes

Full Text available with Trip Pro

2013 Journal of Antimicrobial Chemotherapy

164. Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

Current use of other MS disease-modifying therapies (DMTs) besides glatiramer acetate, IFNβ-1 (any formulation), and the above listed medications. Current use of cimetidine, cyclosporine, dronedarone, lopinavir, probenecid, quinidine (including Neudexta), ranolazine, rifampin, ritonavir, or tipranavir. Clinically significant cardiovascular disease, including myocardial infarct within last 6 months, unstable ischemic heart disease, congestive heart failure or angina Resting pulse < 50 bpm, sinoatrial

2013 Clinical Trials

165. Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs) NNRTI + 2 NRTIs Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs. PI + 2 NRTIs Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs. Outcome Measures Go to Primary Outcome Measures : Medical Outcomes Study-HIV (MOS-HIV) Health Survey Scores [ Time Frame: Week 4 Follow-up

2013 Clinical Trials

166. Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

of EVG in the applicable country. Drug: EVG Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily Other Name: Vitekta® Drug: Background regimen Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed (...) of EVG in the applicable country. Drug: EVG Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily Other Name: Vitekta® Drug: Background regimen Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed

2013 Clinical Trials

167. Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

) greater than 470 msec at 2 or more time points within a 24 hour period or family history of long QT syndrome. Concomitant medication contraindicated for use with rifampicin (including, but not limited to): atazanavir, darunavir, fosamprenavir, ritonavir-boosted saquinavir, saquinavir, or tipranavir. Patients who have jaundice. Patients who weigh less than 50 kg. Clinical judgment by the investigator that the patient should not participate in the study. Contacts and Locations Go to Information from

2013 Clinical Trials

168. Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

formulations of ritonavir, ritonavir/lopinavir, amprenavir and fosamprenavir. Current use of tipranavir or maraviroc. Current use of zidovudine, stavudine or didanosine (as disulfiram potentially has potent irreversible inhibitory effects on mitochondrial metabolism and hence could exacerbate the toxicity of these drugs). Concurrent use of rivaroxaban ( a CYP3A metabolized medication) as the cytochrome P450 inhibitory effects of disulfiram on rivaroxaban are unknown. Current use of warfarin Patients who

2013 Clinical Trials

169. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. (PubMed)

with this regimen for an additional 7 days. Intensive blood samples were taken on days 7 and 14 for pharmacokinetic assessments. In group B, 12 healthy subjects were given BILR 355/r (150 mg/100 mg) b.i.d. for 7 days. The pharmacokinetic data from group B were pooled with data from group B subjects in other similar studies performed in parallel (BILR 355 alone group in BILR 355 drug-drug interaction studies with tipranavir, lopinavir/RTV, and emtricitabine/tenofovir DF; BILR 355 regimen was the same).After co

2012 Journal of clinical pharmacy and therapeutics

170. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. (PubMed)

, using indirect comparison.We included RCTs published in 2003-2010 that assessed the 48-week immunological and virological efficacy of adding new antiretroviral drugs vs. placebo to optimized background therapy (OBT) in treatment-experienced subjects. These drugs included maraviroc, vicriviroc, enfuvirtide, raltegravir, etravirine, tipranavir and darunavir. We collected baseline descriptive characteristics, CD4 cell count changes and virological suppression proportions (percentage with HIV RNA <50

Full Text available with Trip Pro

2012 HIV medicine

171. Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors Against the Initial Autocleavage in Gag-Pol Polyprotein Processing. (PubMed)

, saquinavir, and tipranavir) to block this initial autocleavage step. Of these inhibitors, darunavir and saquinavir were the most effective. Darunavir and saquinavir were also the most effective at blocking the initial autoprocessing of full-length Gag-Pol in HIV-1-infected T cells. Thus, we have identified at least two HIV-1 protease inhibitors that have activity against the primary autocatalytic step of the embedded HIV-1 protease in Gag-Pol at concentrations that may be attained in HIV-1-infected

Full Text available with Trip Pro

2012 Antimicrobial Agents and Chemotherapy

172. Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

12 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir, and St. John?s wort are not eligible; the topical use of these medications (if applicable) is allowed Patients who have an uncontrolled infection are not eligible Patients who have received a prior solid organ transplantation are not eligible Patients who have a primary or metastatic CNS tumor at the time of study enrollment are not eligible; a prior

2012 Clinical Trials

173. Histone Deacetylases

inhibitors during or within 7 days before start of LBH589-treatment (e.g. ketoconazole, itraconazole, clarithromycin, erythromycin, diltiazem, verapamil, delavirdine, indinavir, saquinavir, ritonavir, atazanavir, nelfinavir, grapefruit juice) Administration of potent CYP3A4 inducers during or within 12 days before start of LBH589-treatment (e.g. dexamethasone, rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, St. John´s wort, efavirenz, tipranavir) Ongoing treatment with therapeutic doses

2012 Clinical Trials

174. Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

allergies to etravirine Willingness of subject to adhere to protocol requirements. Exclusion Criteria: Pregnant women with medical or psychological contraindications to breast milk expression. Requirements for prohibited medications: ARV: Tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, and protease inhibitors administered without ritonavir, nonnucleoside reverse transcriptase inhibitor (NNRTIs). Alternative/CAM: St. John's wort Anticonvulsants: Phenobarbital, carbamazepine

2012 Clinical Trials

175. Aura Adolescent PK Study GSK2829332

and moderate pgp inhibitors (e.g. dronedarone,ritonavir, indinavir, quinidine, valspodar, elacridar (GF120918); No use within the following time interval before Visit 1: 4 weeks. Medication: Strong and moderate CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine, ecstasy, terbinafine, cinacalcet, ritonavir, tipranavir, moclobemide, duloxetine, dronedarone); No use within the following time interval before Visit 1: 4 weeks. Medication: Any other investigational drug; No use within the following

2012 Clinical Trials

176. Differential Effects of Ethanol on Spectral Binding and Inhibition of Cytochrome P450 3A4 with Eight Protease Inhibitors Antiretroviral Drugs (PubMed)

-trifluoromethylcoumarin substrate and NADPH at varying concentrations of PIs and ethanol.Atazanavir, lopinavir, saquinavir, and tipranavir showed type I spectral binding, whereas indinavir and ritonavir showed type II. However, amprenavir and darunavir did not show spectral binding with CYP3A4. Ethanol at 20 mM decreased the maximum spectral change (δA(max)) with type I lopinavir and saquinavir, but it did not alter δA(max) with other PIs. Ethanol did not alter spectral binding affinity (K(D)) and inhibition constant

Full Text available with Trip Pro

2011 Alcoholism, clinical and experimental research

177. Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. (PubMed)

in regimens containing the most common antiretroviral agents.Drug-drug interactions between vicriviroc and 11 other antiretroviral compounds were investigated in fixed-sequence or parallel-group clinical trials lasting 12-35 days. Fixed-sequence studies were conducted with the protease inhibitors atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, saquinavir and tipranavir. In these studies vicriviroc was administered with ritonavir for a fixed duration, followed by administration of vicriviroc

2011 Clinical pharmacokinetics

178. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. (PubMed)

(18.2%) patients receiving a regimen combining raltegravir and ritonavir-boosted tipranavir experienced alanine aminotransferase elevations, which led to a switch from tipranavir to darunavir in 8 cases, without discontinuation of raltegravir.In well-suppressed patients with multidrug-resistant HIV infection, a switch from enfuvirtide to raltegravir is generally well tolerated and has sustained antiviral efficacy when combined with a potent background regimen.

Full Text available with Trip Pro

2011 The Journal of antimicrobial chemotherapy

179. In vitro activity against Plasmodium falciparum of antiretroviral drugs. (PubMed)

the concentrations achieved with standard dosing. The effects most likely to be clinically relevant were with HIV protease inhibitors. Of the tested compounds, activity was seen with lopinavir (2.7 to 2.9 μM), atazanavir (3.3 to 13.0 μM), saquinavir (5.0 to 12.1 μM), nelfinavir (6.5 to 12.1 μM), ritonavir (9.5 to 10.9 μM), tipranavir (15.5 to 22.3 μM), and amprenavir (28.1 to 40.8) but not darunavir. Lopinavir was active at levels well below those achieved with standard dosing of coformulated lopinavir-ritonavir

Full Text available with Trip Pro

2011 Antimicrobial Agents and Chemotherapy

180. Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals

or hazardous alcohol use as determined by clinical evaluation. Current use of any drug formulation that contains alcohol or that might contain alcohol. Current use of tipranavir. Current use of maraviroc. Current use of warfarin. Intending to modify antiretroviral therapy in the next 27 weeks for any reason. Serious illness requiring hospitalization or parental antibiotics within preceding 3 months. Severe myocardial disease or coronary artery disease. History of psychosis. Clinically active hepatitis

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>